Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:

With Wyeth, Pfizer To Become Second-largest Multinational Pharma In India

This article was originally published in PharmAsia News

  • News

Executive Summary

MUMBAI - Pfizer's mega buyout of Wyeth for $68 billion is set to further strengthen the Indian businesses of the world's largest drug maker with additional focus on tapping the domestic formulations business and enhancing clinical trials
Table

View full table

Advertisement

Related Content

Pink Sheet
Pfizer To Become Largest Pharma In Japan After Wyeth Merger
Scrip
Pfizer To Become Largest Pharma In Japan After Wyeth Merger
Pink Sheet
Pfizer To Become Largest Pharma In Japan After Wyeth Merger
Scrip
Pfizer To Become Largest Pharma In Japan After Wyeth Merger
Scrip
Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors
Scrip
Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors
Scrip
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
Scrip
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
Scrip
Pfizer, Astellas Execs Talk Deals At BIO Asia
Scrip
India’s DCGI Issues Warning Letter To Wyeth, GVK Over Trial
Advertisement
Tags:
UsernamePublicRestriction

Register

SC069934

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By